Clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics Senhwa Biosciences, Inc. (TPEx: 6492) announced on Friday that its drug Silmitasertib (CX-4945) received Rare Paediatric Disease Designation (RPDD) from the US FDA for neuroblastoma treatment.
This follows a previous RPDD granted for medulloblastoma in July 2020, underscoring Silmitasertib's potential in rare pediatric cancers. Silmitasertib, a first-in-class CK2 inhibitor, demonstrated antitumor activity in pre-clinical neuroblastoma studies.
The RPDD qualifies the drug for the Priority Review Voucher (PRV) program, designed to accelerate the development of novel therapies for rare pediatric diseases. Silmitasertib has already been granted one RPDD and three Orphan Drug Designations (ODD) by the FDA.
Neuroblastoma, predominantly affecting infants and diagnosed on average between 1 and 2 years old, represents the third most common pediatric cancer in the US, with 700 to 800 new cases annually. High-risk neuroblastoma has a 5-year survival rate of approximately 50% and is prone to recurrence despite intensive treatment; no standard treatment exists for relapsed or refractory cases.
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment